{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/mi-secondary-prevention/prescribing-information/beta-blockers/","result":{"pageContext":{"chapter":{"id":"a6c13387-db91-5f87-9795-c95a1be0a245","slug":"beta-blockers","fullItemName":"Beta blockers","depth":2,"htmlHeader":"<!-- begin field d6787637-9efb-4e59-88b0-a78300edcf93 --><h2>Beta-blockers</h2><!-- end field d6787637-9efb-4e59-88b0-a78300edcf93 -->","summary":"","htmlStringContent":"<!-- begin item 99d873be-52d0-4607-b0ff-a78300edcd1f --><!-- end item 99d873be-52d0-4607-b0ff-a78300edcd1f -->","topic":{"id":"10808f6c-5a83-5526-84e2-5998dee92475","topicId":"0b3a22ee-885a-43aa-8d4b-a290dc2afbcc","topicName":"MI - secondary prevention","slug":"mi-secondary-prevention","lastRevised":"Last revised in May 2020","chapters":[{"id":"6d17bc7f-3ed1-5a79-b4f4-8e9dc752c658","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a57b961c-8bba-5c02-8844-b6307b89222c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"dc552ddd-7106-5f5f-a7d9-4b2d6f80e1fa","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e9a32a50-5bdc-5fc0-8ecb-152881ffa7ad","slug":"changes","fullItemName":"Changes"},{"id":"d4c6dcc6-12c6-52a1-957d-47a931a225ec","slug":"update","fullItemName":"Update"}]},{"id":"8c06d36f-1d73-5741-981b-5ed3cc16b7c2","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cd13560d-8bec-5902-9a9e-2ce26eaa9028","slug":"goals","fullItemName":"Goals"},{"id":"b9d35945-0a30-523a-9ded-6a2ea7f5a79a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5c84a4ff-a034-50b3-b1a3-7cfecfb1e65c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"02b0b701-c0f0-542f-b958-8d30a81301fc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f516bbb5-ea19-5f8f-be12-d8f550493156","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"cf211bbf-df50-54c9-b204-ef227db8c62f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3ddc8181-0420-5ae4-8326-2d5ef700203a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f303e07d-da7d-5073-b00b-f3dd008f2594","slug":"definition","fullItemName":"Definition"},{"id":"45810734-c13c-5bbd-b314-88dcbfd54c57","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5488a58d-1964-5d60-a54e-a420fd0daeff","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b05c9d6f-fae2-5624-bc64-e5456fa46e84","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"2dd1d8e3-398b-5765-b249-43150874e311","fullItemName":"Management","slug":"management","subChapters":[{"id":"6854ca49-f0af-50f1-8fd3-a6bb900b4bc4","slug":"secondary-prevention","fullItemName":"Scenario: Secondary prevention"}]},{"id":"a4fb09c9-df2a-5800-954a-58fe23af6127","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e43e8d70-7611-5939-94cb-7cc18a3950a6","slug":"ace-inhibitors","fullItemName":"ACE inhibitors"},{"id":"0220c0cb-0802-5bfa-9d8b-f767f73dbea1","slug":"antiplatelet-treatments","fullItemName":"Antiplatelet treatments"},{"id":"a6c13387-db91-5f87-9795-c95a1be0a245","slug":"beta-blockers","fullItemName":"Beta blockers"},{"id":"064bc21b-4d02-5987-9c23-08b1ca8870d1","slug":"statins","fullItemName":"Statins"}]},{"id":"05c20737-02bb-500e-b3e6-0a506d19e727","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1ae6e3bc-f751-5c4b-a14d-09c72b74424e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a3e487f8-13d0-532b-b16f-d448106af2ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"03c8dfe8-3b8b-5c16-ab71-21f98aa13dcd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a1919ef1-18db-59ab-8c6d-7ef4d649f5d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3e57d884-d476-55de-a85c-a5e4e2001343","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e8c5059d-6ccf-58a3-bb80-1a8273c64c14","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bcfd412e-e461-5a99-a38f-a03a01873fa5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a4fb09c9-df2a-5800-954a-58fe23af6127","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"10e4105c-bbe3-594c-83b2-d07940044852","slug":"general-information","fullItemName":"General information","depth":3,"htmlHeader":"<!-- begin field 6fe86436-0682-4369-9a4c-aa1400f4a14e --><h3>General information</h3><!-- end field 6fe86436-0682-4369-9a4c-aa1400f4a14e -->","summary":"","htmlStringContent":"<!-- begin item 8d26f497-9fdf-4198-9ec5-aa1400f4a0e6 --><!-- begin field 09fc362d-f297-4bf6-8eef-aa1400f4a14e --><ul><li><strong>Beta-blocker:</strong><ul><li>The dose may need to be titrated upwards until the maximum tolerated or target dose is reached — details of current and any target dose should have been provided by the initial prescriber in the discharge plan.</li><li>A beta-blocker should be continued for at least 12 months after an MI in people without left ventricular systolic dysfunction or heart failure.</li><li>A beta-blocker should be continued indefinitely if the person has left ventricular systolic dysfunction.</li><li>It may be appropriate to offer a beta-blocker to anyone not already taking one who has had an MI more than 12 months ago and who has left ventricular systolic dysfunction, whether or not they have symptoms. For advice on the management of people with heart failure plus left ventricular dysfunction, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>.<ul><li>Do not offer people without left ventricular systolic dysfunction or heart failure, who have had an MI more than 12 months ago, treatment with a beta-blocker unless there is an additional clinical indication for a beta-blocker.</li></ul></li><li>For further detailed information on prescribing a beta-blocker, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>.</li><li>Patient information leaflets on use of beta blockers in pregnancy are freely available from the UK Teratology Information Service at <a data-hyperlink-id=\"8102b07d-7088-473d-a974-aa14015ef468\" href=\"http://www.medicinesinpregnancy.org/\">www.medicinesinpregnancy.org</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">NICE, 2013</a>]</p><!-- end field 09fc362d-f297-4bf6-8eef-aa1400f4a14e --><!-- end item 8d26f497-9fdf-4198-9ec5-aa1400f4a0e6 -->","subChapters":[]},{"id":"0ecf4fd0-3bc5-51f5-9ddc-0d6d2603e9f6","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e81e930d-db9c-4be1-81c1-aa1400f4b1f6 --><h3>Contraindications and cautions</h3><!-- end field e81e930d-db9c-4be1-81c1-aa1400f4b1f6 -->","summary":"","htmlStringContent":"<!-- begin item 8c4b1118-ab8e-4a83-9ec1-aa1400f4b1b5 --><!-- begin field 15d992d5-8a5a-42d8-bc4e-aa1400f4b1f6 --><ul><li><strong>Do not prescribe beta-blockers to people with:</strong><ul><li>A history of obstructive airways disease (such as asthma and chronic obstructive pulmonary disease) or bronchospasm. However, if there is no alternative, a cardioselective beta-blocker (such as bisoprolol and atenolol) can be used under specialist supervision.<ul><li>Treatment should be initiated at the lowest possible dose and the person should be monitored for new symptoms (such as dyspnea or exercise intolerance). Concomitant bronchodilator therapy is recommended.</li></ul></li><li>Cardiogenic shock or phaeochromocytoma (without a concomitant alpha-blocker).</li><li>Second- or third-degree heart block (in the absence of a permanent pacemaker).</li><li>Sick sinus syndrome.</li><li>Sinus bradycardia (heart rate less than 60 beats per minute at the start of treatment).</li><li>Severe hypotension (systolic less than 100 mmHg).</li><li>Severe peripheral arterial disease (pain at rest and sometimes intermittent claudication) — the blood pressure-lowering properties of beta-blockers can exacerbate symptoms.</li><li>Uncontrolled heart failure.<ul><li>Seek specialist advice before starting a beta-blocker in people with a current or recent exacerbation of heart failure.</li></ul></li></ul></li><li><strong>Beta-blockers should be used with caution in people with:</strong><ul><li>Diabetes.</li><li>First-degree atrioventricular (AV) block.</li><li>Myasthaenia gravis.</li><li>Portal hypertension — due to risk of deteriorating liver function.</li><li>Psoriasis.</li><li><strong>Note:</strong> Be aware that use of a beta-blocker can mask symptoms of hypoglycaemia and thyrotoxicosis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">BNF 76, 2018</a>]</p><!-- end field 15d992d5-8a5a-42d8-bc4e-aa1400f4b1f6 --><!-- end item 8c4b1118-ab8e-4a83-9ec1-aa1400f4b1b5 -->","subChapters":[]},{"id":"479315d6-f76b-5053-948b-50288f8a4465","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 7c0b543b-b515-4134-8395-aa1400f4bf98 --><h3>Adverse effects</h3><!-- end field 7c0b543b-b515-4134-8395-aa1400f4bf98 -->","summary":"","htmlStringContent":"<!-- begin item 2b5cbe1c-7b0d-4ba4-9815-aa1400f4bf5b --><!-- begin field ca98a8ee-2c7e-4d5d-ac55-aa1400f4bf98 --><p><strong>Adverse effects of beta-blockers include:</strong></p><ul><li>Bradycardia.</li><li>Bronchospasm.</li><li>Cold extremities, paraesthesiae, and numbness — these are more common in people with peripheral vascular disease.<ul><li>If troublesome, beta-blockers might need to be stopped.</li></ul></li><li>Conduction disorders.</li><li>Dizziness.</li><li>Dyspnoea.</li><li>Exacerbation of psoriasis.</li><li>Exacerbation of Raynaud's phenomenon.</li><li>Fatigue — an incidence of approximately 18 per 1,000 people treated with a beta-blocker has been reported.</li><li>Gastrointestinal disturbances.</li><li>Headache.</li><li>Heart failure.</li><li>Hyperglycaemia/hypoglycaemia — in people with or without diabetes.</li><li>Hypotension.</li><li>Impotence and loss of libido — occurs in approximately five people per 1,000 receiving treatment.</li><li>Paraesthesia.</li><li>Peripheral vasoconstriction.</li><li>Psychoses.</li><li>Purpura.</li><li>Sleep disturbance or nightmares — this occurs less frequently with water-soluble beta-blockers, such as atenolol, because these drugs are less likely to cross the blood-brain barrier.</li><li>Thrombocytopenia.</li><li>Vertigo.</li><li>Visual disturbances.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">BNF 76, 2018</a>]</p><!-- end field ca98a8ee-2c7e-4d5d-ac55-aa1400f4bf98 --><!-- end item 2b5cbe1c-7b0d-4ba4-9815-aa1400f4bf5b -->","subChapters":[]},{"id":"3d6f7433-35f8-56de-8fe0-ea3de51c7ff3","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field f152eb6f-cd50-4cdb-8fb3-aa1400f4cbed --><h3>Drug interactions</h3><!-- end field f152eb6f-cd50-4cdb-8fb3-aa1400f4cbed -->","summary":"","htmlStringContent":"<!-- begin item 14fbd7c1-6828-41fb-aa39-aa1400f4cbaf --><!-- begin field 407079a6-425b-4954-87bb-aa1400f4cbed --><p><strong>Key drug interactions with beta-blockers include:</strong></p><ul><li><strong>Alpha-blockers, alprostadil, ACE-inhibitors, angiotensin II receptor antagonists, anxiolytics, baclofen, co-beneldopa, co-careldopa, diazoxide, diuretics. hydralazine, hypnotics, levodopa, MAOIs, methyldopa, minoxidil, moxonidine, nitrates, phenothiazines, sodium nitroprusside, tizanidine </strong>— enhanced hypotensive effect.</li><li><strong>Antidepressants</strong><ul><li>Tricyclics, mirtazapine, and trazodone should be prescribed with caution in people taking beta-blockers, as there is an increased risk of postural hypotension.</li></ul></li><li><strong>Antidiabetics</strong> — beta-blockers may mask warning signs of hypoglycaemia, such as tremor.</li><li><strong>Calcium channel blockers</strong><ul><li>The combination of a beta-blocker and verapamil should not be prescribed because bradycardia, asystole, severe hypotension, and heart failure can occur.</li><li>Caution should be used if prescribing diltiazem with a beta-blocker — monitor pulse and blood pressure carefully, as bradycardia and atrioventricular block can occur. Asystole and sudden death have also been reported.</li><li>The combination of a beta-blocker and nifedipine can cause severe hypotension and heart failure.</li><li>The combination of a beta-blocker and other calcium channel blockers can lead to enhanced antihypertensive effect.</li></ul></li><li><strong>Class I </strong><strong>anti-arrhythmics</strong><strong> (such as quinidine, flecainide)</strong><ul><li>The combination of a beta-blocker and a class I anti-arrhythmic is not recommended because bradycardia and myocardial depression can occur.</li></ul></li><li><strong>Class III </strong><strong>anti-arrhythmics</strong><strong> (such as amiodarone)</strong><ul><li>The combination of a beta-blocker and amiodarone should be prescribed with caution as there is an increased risk of bradycardia, atrioventricular (AV) block, and myocardial depression — monitor pulse and blood pressure and check for signs of worsening heart failure.</li></ul></li><li><strong>Clonidine </strong>— increased risk of withdrawal hypertension. Withdraw beta-blockers several days before slowly withdrawing clonidine.</li><li><strong>Corticosteroids, oestrogens</strong> — hypotensive effect antagonised with concomitant use.</li><li><strong>Digoxin</strong><ul><li>Concomitant administration of a beta-blocker and digoxin can reduce heart rate and prolong AV conduction time, increasing the risk of AV block and bradycardia. Monitor the pulse carefully; consider monitoring with electrocardiography (ECG).</li><li>An increase in plasma digoxin levels has been noted with carvedilol — monitor for signs of digoxin toxicity (confusion, anorexia, nausea, disturbance of colour vision) when starting, adjusting, or stopping carvedilol.</li></ul></li><li><strong>Dobutamine</strong> — increased risk of severe hypertension and bradycardia when non-cardioselective beta-blockers (nadolol, oxprenolol, pindolol, propranolol, timolol) are given with dobutamine.</li><li><strong>Fingolimod, mefloquine</strong> — increased risk of bradycardia </li><li><strong>Moxisylyte </strong>— increased risk of severe postural hypotension.</li><li><strong>Non-steroidal anti-inflammatory drugs</strong> — hypotensive effect antagonised with concomitant use.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">BNF 76, 2018</a>]</p><!-- end field 407079a6-425b-4954-87bb-aa1400f4cbed --><!-- end item 14fbd7c1-6828-41fb-aa39-aa1400f4cbaf -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}